Bicara Therapeutics (NASDAQ:BCAX) Stock Price Target Lowered at Stifel Nicolaus

Bicara Therapeutics (NASDAQ:BCAX) had its price objective decreased by stock analysts at Stifel Nicolaus from $45.00 to $43.00 in a report released on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus‘s price target suggests a potential upside of 330.86% from the company’s previous close.

Other equities research analysts also recently issued research reports about the company. BTIG Research dropped their price objective on Bicara Therapeutics from $39.00 to $37.00 and set a “buy” rating for the company in a report on Tuesday. BMO Capital Markets initiated coverage on Bicara Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $35.00 target price on the stock. Wells Fargo & Company raised their target price on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 12th. Morgan Stanley restated an “overweight” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 20th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Bicara Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $31.75.

Bicara Therapeutics Stock Performance

Shares of BCAX stock opened at $9.98 on Tuesday. Bicara Therapeutics has a 52-week low of $7.87 and a 52-week high of $30.99. The stock has a market cap of $660.38 million, a PE ratio of -3.22 and a beta of -0.33. The firm’s 50 day moving average price is $17.89 and its two-hundred day moving average price is $20.91.

Bicara Therapeutics (NASDAQ:BCAX) last issued its earnings results on Monday, November 9th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.22). As a group, sell-side analysts predict that Bicara Therapeutics will post -3.49 earnings per share for the current fiscal year.

Insider Transactions at Bicara Therapeutics

In other Bicara Therapeutics news, CEO Ryan Cohlhepp sold 17,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the sale, the chief executive officer directly owned 181,641 shares in the company, valued at approximately $4,159,578.90. This trade represents a 8.79% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

Several large investors have recently made changes to their positions in BCAX. Sterling Capital Management LLC increased its position in shares of Bicara Therapeutics by 457.0% in the third quarter. Sterling Capital Management LLC now owns 1,387 shares of the company’s stock valued at $26,000 after acquiring an additional 1,138 shares during the last quarter. Profund Advisors LLC boosted its position in Bicara Therapeutics by 7.2% during the third quarter. Profund Advisors LLC now owns 16,880 shares of the company’s stock valued at $314,000 after purchasing an additional 1,140 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Bicara Therapeutics by 15.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,074 shares of the company’s stock valued at $224,000 after purchasing an additional 1,617 shares during the last quarter. Quantinno Capital Management LP grew its stake in Bicara Therapeutics by 16.1% in the first quarter. Quantinno Capital Management LP now owns 17,612 shares of the company’s stock valued at $350,000 after purchasing an additional 2,447 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in Bicara Therapeutics in the third quarter valued at approximately $63,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.